The first breath test for use in children ages 3 to 17 years to detect Helicobacter pylori (H. pylori) bacterial infections, responsible for chronic stomach inflammation (gastritis) and ulcers, has been approved by the Food and Drug Administration (FDA).
The FDA first cleared the BreathTek UBT test for adults in 1996. The U.S. Centers for Disease Control and Prevention (CDC) estimates that approximately two-thirds of the worlds population is infected with H. pylori. Most people with this infection never have any symptoms but have a two- to six-fold increased risk of developing gastric cancer and mucosal-associated-lymphoid-type lymphoma compared with uninfected people.
Results from this test, when considered with a physicians assessment of the patients history, other risk factors, and professional guidelines, can quickly indicate infection, which allows a physician to initiate appropriate health measures in a timely manner, says Alberto Gutierrez, PhD, director of the Office of In Vitro Diagnostic Device Evaluation and Safety in FDAs Center for Devices and Radiological Health.
The FDA based its approval of the BreathTek UBT test for children on a multi-center study of 176 patients, comparing its performance to a composite reference method and demonstrating 95.8 percent sensitivity and 99.2 percent specificity. An additional study was done at 1 to 6 months after therapy to support use for post-treatment monitoring of patients. The sensitivity was 83.3 percent and the specificity was 100 percent.
BreathTek UBT is manufactured by Otsuka America Pharmaceutical based in Rockville, Md.